

MAY 14 2001

Complete in ink

**INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Application Number

09/689,430

Filing Date

10/12/00

First Named Inventor

Walsh, et al.

Group Art Unit

1642

Examiner Name

To be Assigned

RECEIVED

MAY 16 2001

TECH CENTER 1600/2900

Attorney Docket Number

5052-53

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	T ⁶
		Office ³	Number ⁴ (if known) ⁵				
22		WO	97/45550	✓ ZHANG, W.	12-04-1997		
23		WO	98/09524	✓ SRIVASTAVA, A.	03-12-1998		
24		WO	99/61642	✓ SNYDER, R.	12-02-1999		
25		WO	00/23116	✓ COUTO, L.	04-27-2000		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
26		CHAO, H., et al., Sustained Expression of Human Factor VIII in Mice Using a Parvovirus-Based Vector (2000) Blood, Vol. 95(5), pp. 1594-1599	
27	✓	ILL, C., et al., Optimization of the Human Factor VIII Complementary DNA Expression Plasmid for Gene Therapy of Hemophilia A (1997) Blood Coagulation & Fibrinolysis, Vol. 8(2), pp. S23-S30	
28		Wang, L, et al., Sustained Correction of Bleeding Disorder in Hemophilia B Mice by Gene Therapy (1999) Proc. Natl. Acad. Sci. USA Vol. 96, pp. 3906-3910	

Examiner Signature		Date Considered	11/19/01
--------------------	---	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2095839v1

¹ Unique citation designation number.² See attached Kinds of U.S. Patent Documents.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place an "X" here if English language Translation is attached.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT





(Use as many sheets as necessary)

Application Number	09/689,740
Filing Date	October 12, 2000
First Named Inventor	Walsh <i>et al.</i>
Group Art Unit	1642
Examiner Name	Not Assigned


O I P E
APR 02 2001
PATENT & TRADEMARK OFFICERECEIVED
APR 13 2001
Technology Center 2100

Docket 2 of 2 Attorney Docket Number 35052/204373(5052-53)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	13	CONNELLY <i>et al.</i> , "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> , November 15, 1996, Vol. 88, No. 10, pp. 3846-3853	
	14 ✓	CONNELLY <i>et al.</i> , "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> , May 1, 1998, Vol. 91, No. 9, pp. 3273-3281	
	15 ✓	DONG <i>et al.</i> , "Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus," <i>Human Gene Therapy</i> , November 10, 1996, Vol. 7, pp. 2111-2112	
	16 ✓	DWARKI <i>et al.</i> , "Gene Therapy for Hemophilia A: Production of Therapeutic Levels of Human Factor VIII in Vivo in Mice," <i>Proc. Natl. Acad. Sci. USA</i> , February 1995, Vol. 92, pp. 1023-1027	
	17 ✓	GNATENKO <i>et al.</i> , "Human Factor VIII can be Packaged and Functionally Expressed in an Adeno-Associated Virus Background: Applicability to Haemophilia A Gene Therapy," <i>British Journal of Haematology</i> , 1999, Vol. 104, pp. 27-36	
	18 ✓	HERZOG <i>et al.</i> , "Problems and Prospects in Gene Therapy for Hemophilia," <i>Current Opinion in Hematology</i> , 1998, pp. 321-326	
	19 ✓	KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> , October 1, 1993, Vol. 262, pp. 117-119	
	20 ✓	LOZIER <i>et al.</i> , "Gene Therapy and the Hemophilias," <i>JAMA</i> , January 5, 1994, Vol. 271, No. 1, Pp. 47-51	
	21 ✓	RUSSELL <i>et al.</i> , "Adeno-Associated Virus Vectors and Hematology," <i>Blood</i> , August 1, 1999, Vol. 94, No. 3., pp. 864-874	

RTA01/2093596v1

Examiner Signature		Date Considered	11/19/01
--------------------	---	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	09/689,413
Filing Date	October 12, 2000
First Named Inventor	Walsh <i>et al.</i>
Group Art Unit	1642
Examiner Name	Not Assigned

RECEIVED

APR 13 2001

Technology Center 2100

Attorney Docket Number 35052/204373(5052-53)

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	5,750,172		Meade <i>et al.</i>	05-12-1998
	2	5,843,742		Natsoulis <i>et al.</i>	12-01-1998
	3	5,856,152		Wilson <i>et al.</i>	01-05-1999
	4	5,858,775		Johnson	01-12-1999
	5	5,866,696		Carter <i>et al.</i>	02-02-1999
	6	5,871,986		Boyce	02-16-1999
	7	5,880,327		Lubon <i>et al.</i>	03-09-1999
	8	5,885,971		German <i>et al.</i>	03-23-1999
	9	6,200,560		Couto <i>et al.</i>	03-13-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	10	BARTLETT <i>et al.</i> , "Genetics and Biology of Adeno-Associated Virus," <i>Viral Vectors, Gene Therapy and Neuroscience Applications</i> (1995), pp. 55-73, Edited by Kaplitt and Loewy, Academic Press, Inc.	
	11 ✓	CHUAH <i>et al.</i> , "Gene Therapy for Hemophilia: Hopes and Hurdles," <i>Critical Reviews in Oncology/Hematology</i> (1998) Vol. 28, pp. 153-171	
	12 ✓	CONNELLY <i>et al.</i> , "Sustained Expression of Therapeutic Levels of Human Factor VIII in Mice," <i>Blood</i> , June 1, 1996, Vol. 87, No. 11, pp. 4671-4677	

Examiner Signature	<i>James L.</i>	Date Considered	11/19/01
--------------------	-----------------	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.